MP
SLN

Mangrove Partners’s Silence Therapeutics SLN Stock Holding History

Mangrove Partners’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-385,408
Closed -$7.01M – 195
2024
Q3 		$7.01M Hold
385,408
– – 0.6% 47
2024
Q2 		$7.32M Hold
385,408
– – 0.56% 56
2024
Q1 		$8.32M Buy
+385,408
New +$8.38M 0.58% 53

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Mangrove Partners's SLN Position: Q4 2024 in Review

Mangrove Partners sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 385,408 shares — an estimated $7.01M sold.

Mangrove Partners first reported a position in SLN in Q1 2024 and held it in 3 quarters. The position peaked at $8.32M in Q1 2024. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • Mangrove Partners reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Mangrove Partners sold 385,408 Silence Therapeutics shares in Q4 2024, an estimated $7.01M.
  • Mangrove Partners first reported a position in Silence Therapeutics in Q1 2024 and held it in 3 quarters.
  • Mangrove Partners's Silence Therapeutics position peaked at $8.32M in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on Mangrove Partners's 13F filing for Q4 2024, filed 14 Feb 2025.